Patients taking diabetes medications or blood pressure medications should be especially careful because weight loss and appetite changes may alter medication needs
Our results are conducive to further understanding the regulatory effect of GLP-1R on glucose metabolism in the central nervous system, and provide a theoretical basis for the future development of GLP-1R-related drugs
Maintain a minimum distance of 23 centimetres between injection sites, even within the same anatomical area
Age-associated cholesterol reduction triggers brain insulin resistance by facilitating ligand-independent receptor activation and pathway desensitization
Combining with DPP-4 inhibitors is generally not recommended, as both drug classes work on the incretin system Adding basal insulin for those with more significant hyperglycaemia, which can be used alongside GLP-1 medications (with careful monitoring for hypoglycaemia) Switching to insulin therapy entirely may be necessary for those with advanced beta cell failure For weight management , when GLP-1 medications don't produce adequate weight loss, alternatives include: Orlistat , a lipase inhibitor that reduces fat absorption, though weight loss is typically modest (2-3 kg on average) Naltrexone-bupropion (Mysimba), which works on appetite centres through different pathways
Our study found that patients using semaglutide 1 mg have a higher risk of depression, anxiety, and suicidal ideation when compared with non-semaglutide users, irrespective of age and sex differences
/assets/images/provider/photos/2766296.jpeg)
